Novartis is fighting against the use of a low-cost drug option, which rival its Lucentis eye medication, in various portions of Britain, reported Reuters. Lucentis brings in annualized sales worth around $2bn and is an age-related mascular degeneration (AMD) medication that is recommended by the National institute for Health and Clinical Excellence in Britain, according […]